Zentalis Pharmaceuticals, Inc. (ZNTL) Stock Grade

About Zentalis Pharmaceuticals, Inc.'s fundamentals

Zentalis Pharmaceuticals is a biotech company with a market capitalization of $185.1 million that reported a net loss in its latest annual statement, resulting in a zero net margin and no earnings per share. The company experienced a significant contraction with revenue declining 100% year-over-year, indicating it is no longer generating product revenue. With no dividend yield and an inability to calculate traditional profitability metrics like price-to-earnings or return on equity, the company's financial position reflects the early or transitional stage typical of development-stage biotechnology firms.